JP6946436B2 - （アザ）インドール−、ベンゾチオフェン−、及びベンゾフラン−３−スルホンアミド - Google Patents

（アザ）インドール−、ベンゾチオフェン−、及びベンゾフラン−３−スルホンアミド Download PDF

Info

Publication number
JP6946436B2
JP6946436B2 JP2019535368A JP2019535368A JP6946436B2 JP 6946436 B2 JP6946436 B2 JP 6946436B2 JP 2019535368 A JP2019535368 A JP 2019535368A JP 2019535368 A JP2019535368 A JP 2019535368A JP 6946436 B2 JP6946436 B2 JP 6946436B2
Authority
JP
Japan
Prior art keywords
chloro
sulfonamide
fluoro
unsubstituted
indol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019535368A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020504753A (ja
JP2020504753A5 (https=
Inventor
イー． ミューラー、クリスタ
イー． ミューラー、クリスタ
ペグリエール、セシル
ルイス ロバート デリグニー、マイケル
ルイス ロバート デリグニー、マイケル
− タイエブ、アリ エル
− タイエブ、アリ エル
ホッケマイヤー、イェルク
ルデック、マリー
メルシエール、ジョエル
プロバン、ローラン
エム． ボシュタ、ナデル
エム． ボシュタ、ナデル
バーッタライ、サンジェイ
ナマシバヤム、ビグネシュワラン
フンケ、マリオ
シュバッハ、ルーカス
ゴロス、サブリナ
ラオフェンベルク、ダニエル フォン
ラオフェンベルク、ダニエル フォン
バーレ、アナイス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB Pharma GmbH
Original Assignee
UCB Pharma GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCB Pharma GmbH filed Critical UCB Pharma GmbH
Publication of JP2020504753A publication Critical patent/JP2020504753A/ja
Publication of JP2020504753A5 publication Critical patent/JP2020504753A5/ja
Priority to JP2021150157A priority Critical patent/JP7270011B2/ja
Application granted granted Critical
Publication of JP6946436B2 publication Critical patent/JP6946436B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/90—Benzo [c, d] indoles; Hydrogenated benzo [c, d] indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D421/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having selenium, tellurium, or halogen atoms as ring hetero atoms
    • C07D421/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having selenium, tellurium, or halogen atoms as ring hetero atoms containing two hetero rings
    • C07D421/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having selenium, tellurium, or halogen atoms as ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Indole Compounds (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
JP2019535368A 2016-12-28 2017-12-27 （アザ）インドール−、ベンゾチオフェン−、及びベンゾフラン−３−スルホンアミド Active JP6946436B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021150157A JP7270011B2 (ja) 2016-12-28 2021-09-15 （アザ）インドール－、ベンゾチオフェン－、及びベンゾフラン－３－スルホンアミド

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16207137.7 2016-12-28
EP16207137 2016-12-28
PCT/EP2017/084602 WO2018122232A1 (en) 2016-12-28 2017-12-27 (aza)indole-, benzothiophene-, and benzofuran-3-sulfonamides

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021150157A Division JP7270011B2 (ja) 2016-12-28 2021-09-15 （アザ）インドール－、ベンゾチオフェン－、及びベンゾフラン－３－スルホンアミド

Publications (3)

Publication Number Publication Date
JP2020504753A JP2020504753A (ja) 2020-02-13
JP2020504753A5 JP2020504753A5 (https=) 2020-04-02
JP6946436B2 true JP6946436B2 (ja) 2021-10-06

Family

ID=57614285

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019535368A Active JP6946436B2 (ja) 2016-12-28 2017-12-27 （アザ）インドール−、ベンゾチオフェン−、及びベンゾフラン−３−スルホンアミド
JP2021150157A Active JP7270011B2 (ja) 2016-12-28 2021-09-15 （アザ）インドール－、ベンゾチオフェン－、及びベンゾフラン－３－スルホンアミド

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021150157A Active JP7270011B2 (ja) 2016-12-28 2021-09-15 （アザ）インドール－、ベンゾチオフェン－、及びベンゾフラン－３－スルホンアミド

Country Status (25)

Country Link
US (4) US11345662B2 (https=)
EP (1) EP3562820A1 (https=)
JP (2) JP6946436B2 (https=)
KR (1) KR102537100B1 (https=)
CN (3) CN116283712B (https=)
AR (1) AR110592A1 (https=)
AU (2) AU2017387695B2 (https=)
CL (1) CL2019001660A1 (https=)
CO (1) CO2019007829A2 (https=)
CR (1) CR20190287A (https=)
EA (1) EA201991553A1 (https=)
EC (1) ECSP19044183A (https=)
IL (2) IL295047B2 (https=)
MX (1) MX2019006190A (https=)
MY (1) MY199872A (https=)
NZ (1) NZ753651A (https=)
PE (1) PE20191475A1 (https=)
PH (1) PH12019501095A1 (https=)
RU (1) RU2767904C2 (https=)
TN (1) TN2019000165A1 (https=)
TW (1) TWI754702B (https=)
UA (1) UA127890C2 (https=)
UY (1) UY37554A (https=)
WO (1) WO2018122232A1 (https=)
ZA (1) ZA201903466B (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021527696A (ja) * 2018-06-20 2021-10-14 ウーツェーベー ファルマ ゲーエムベーハー 置換されたアルコキシピリジニルインドールスルホンアミド
JP2022003051A (ja) * 2016-12-28 2022-01-11 ウーツェーベー ファルマ ゲーエムベーハー （アザ）インドール−、ベンゾチオフェン−、及びベンゾフラン−３−スルホンアミド

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018119142A1 (en) 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
CN112262141A (zh) * 2018-04-20 2021-01-22 弗吉尼亚理工大学知识产权有限公司 可用作线粒体解偶联剂的咪唑吡啶
TWI857957B (zh) 2018-06-19 2024-10-11 德商Ｕｃｂ製藥有限公司 吡啶基及吡基-（氮）吲哚磺醯胺
WO2020051099A1 (en) * 2018-09-03 2020-03-12 Genentech, Inc. Carboxamide and sulfonamide derivatives useful as tead modulators
CN110128422B (zh) * 2019-01-04 2022-03-18 金凯(辽宁)生命科技股份有限公司 5-甲氧基-7-氮杂吲哚的合成方法
MA54753A (fr) * 2019-01-17 2021-11-24 Ifm Due Inc Composés et compositions pour traiter des états pathologiques associés à une activité de sting
GB201903671D0 (en) * 2019-03-18 2019-05-01 Univ Edinburgh Small molecule photosensitizers for photodynamic therapy
EP3983384B1 (en) * 2019-06-17 2023-10-11 UCB Pharma GmbH N-(phenyl)-indole-3-sulfonamide derivatives and related compounds as gpr17 modulators for treating cns disorders such as multiple sclerosis
US20230167406A1 (en) * 2020-05-01 2023-06-01 The Children's Medical Center Corporation Compositions and methods of promoting myelination
CN112375027B (zh) * 2020-12-07 2023-03-31 中国药科大学 吲哚磺酰胺类衍生物及其医药用途
CN112266328B (zh) * 2020-12-09 2023-11-03 郑州萃智医药科技有限公司 3-氟-4-硝基苯甲醛的合成路线及制备方法
PE20240125A1 (es) 2021-02-26 2024-01-22 Hoffmann La Roche Derivados novedosos de pirimidin-2-il sulfonamida
EP4347558A1 (en) * 2021-06-04 2024-04-10 ReWind Therapeutics NV 3-pyrrolylsulfonamide compounds as gpr17 antagonists
UY39892A (es) 2021-08-10 2023-03-31 Novartis Pharma Ag Compuestos y composiciones para tratar afecciones asociadas con la actividad de STING
CN114276319B (zh) * 2022-01-06 2023-11-03 滁州学院 一种劳拉替尼中间体的合成方法
CN114315741B (zh) * 2022-01-19 2023-09-12 贵州医科大学 一种硫代化合物及其制备方法与应用
WO2024017863A1 (en) 2022-07-20 2024-01-25 F. Hoffmann-La Roche Ag Novel pyrimidinyl and triazinyl sulfonamide derivatives
WO2024017856A1 (en) 2022-07-20 2024-01-25 F. Hoffmann-La Roche Ag Novel isoquinolinone, pyrrolopyridinone and thienopyridinone sulfonamide derivatives
CN119585264A (zh) 2022-07-20 2025-03-07 豪夫迈·罗氏有限公司 新颖异噻唑-3-基和异噁唑-3-基磺酰胺化合物
US20260027104A1 (en) 2022-07-20 2026-01-29 Hoffmann-La Roche Inc. Novel naphthyl and isoquinoline sulfonamide derivatives
EP4558498A1 (en) * 2022-07-20 2025-05-28 F. Hoffmann-La Roche AG Novel imidazopyridine and pyrazolopyridine sulfonamide derivatives
EP4619402A1 (en) * 2022-11-20 2025-09-24 Myrobalan Therapeutics, Inc. Gpr17 modulators and uses thereof
AU2023401169A1 (en) * 2022-12-02 2025-05-29 Rewind Therapeutics Nv Fused pyrrolyl-sulfonamide compounds
WO2024153233A1 (en) * 2023-01-19 2024-07-25 Nanjing Immunophage Biotech Co., Ltd Compounds and their uses as gpr17 antagonists
CN116947879B (zh) * 2023-07-25 2025-10-31 沈阳药科大学 一种bbi608类衍生物及其制备方法和在制备治疗stat3介导疾病的药物中的应用
TW202515863A (zh) * 2023-08-15 2025-04-16 美商百健Ｍａ公司 作為ｇｐｒ１７調節劑之吲哚及吡咯并吡啶衍生物
WO2025195241A1 (zh) * 2024-03-19 2025-09-25 迈巴制药(南京)有限公司 Gpr17受体抑制剂及其用途
GB202508013D0 (en) 2024-05-23 2025-07-09 Pheno Therapeutics Ltd Compunds
GB2700773A (en) 2024-05-23 2026-03-11 Pheno Therapeutics Ltd Compounds
GB2642355A (en) 2024-07-05 2026-01-07 Pheno Therapeutics Ltd Polymorphs

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19814084B4 (de) 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
WO2000050391A1 (en) * 1999-02-26 2000-08-31 Merck & Co., Inc. Novel sulfonamide compounds and uses thereof
US6521658B1 (en) * 1999-05-28 2003-02-18 Abbott Laboratories Cell proliferation inhibitors
SE9904750D0 (sv) 1999-12-23 1999-12-23 Pharmacia & Upjohn Ab New formulation, use and method
WO2002092585A1 (en) * 2001-05-11 2002-11-21 Biovitrum Ab Novel, arylsusfonamide compounds for the treatment of obesity, type ii diabetes and cns-disorders
SE0102048D0 (sv) * 2001-06-11 2001-06-11 Pharmacia Ab New Compounds
US7833722B2 (en) 2004-04-27 2010-11-16 Takeda Pharmaceutical Company Limited Ligands for G protein-coupled receptor protein and use thereof
ITMI20042007A1 (it) 2004-10-21 2005-01-21 Consiglio Nazionale Ricerche "modulatori del ricettore gpr17 e loro impieghi terapeutici"
WO2009000262A1 (de) 2007-06-25 2008-12-31 Acino Ag Elektrophoretisches transdermales applikationssystem
BRPI0821915A2 (pt) * 2007-12-26 2015-06-16 Sanofi Aventis Piridil-n-(1,3,4)-tiadiazol-2-il-benzeno sulfonamidas cíclicas, processos para sua preparação e seu uso como produtos farmacêuticos
WO2010032257A1 (en) * 2008-09-17 2010-03-25 Suven Life Sciences Limited Aryl indolyl sulfonamide compounds and their use as 5-ht6 ligands
WO2010126002A1 (ja) * 2009-04-28 2010-11-04 塩野義製薬株式会社 ヘテロ環スルホンアミド化合物を含有する医薬
WO2011113032A2 (en) 2010-03-11 2011-09-15 Swinford Jerry L Method and apparatus for washing dowhole tubulars and equipment
EP2567698B1 (en) * 2011-09-07 2014-02-12 Rheinische Friedrich-Wilhelms-Universität Bonn GPR 17 agonists and screening assay
EP2850068B1 (en) * 2012-05-09 2019-05-29 Universita' degli Studi di Milano N-(phenyl)-2-[[3-(phenyl)-1H-1,2,4-triazol-5-yl]thio]-acetamide derivatives and related compounds as G protein coupled receptor 17 (GPCR17) modulators for use in the treatment of neuro-degenerative diseases
RU2519546C1 (ru) * 2013-01-16 2014-06-10 Общество С Ограниченной Ответственностью "Биоинтегратор" (Ооо "Биоинтегратор") КОНЪЮГАТЫ И МАЛЫЕ МОЛЕКУЛЫ, ВЗАИМОДЕЙСТВУЮЩИЕ С РЕЦЕПТОРОМ CD16а
EP2998294A1 (en) * 2014-09-16 2016-03-23 Sanofi Naphthyl sulfonamide phenyl derivatives as KEAP-1 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders
EP2997966A1 (en) * 2014-09-16 2016-03-23 Sanofi Naphthyl Sulfonamide Pyrrolidine Derivatives as KEAP-1 Modulators for the Treatment of Diabetes, Obesity, Dyslipidemia and Related Disorders
WO2016089062A2 (en) * 2014-12-02 2016-06-09 C&C Research Laboratories Heterocyclic derivatives and use thereof
CN108699008B (zh) * 2016-02-05 2021-10-08 Ea制药株式会社 磺酰胺衍生物和含有其的药物组合物
TWI754702B (zh) 2016-12-28 2022-02-11 德商Ｕｃｂ製藥有限公司 （氮雜）吲哚－和苯並呋喃－３－磺醯胺類

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022003051A (ja) * 2016-12-28 2022-01-11 ウーツェーベー ファルマ ゲーエムベーハー （アザ）インドール−、ベンゾチオフェン−、及びベンゾフラン−３−スルホンアミド
JP2021527696A (ja) * 2018-06-20 2021-10-14 ウーツェーベー ファルマ ゲーエムベーハー 置換されたアルコキシピリジニルインドールスルホンアミド
JP7371031B2 (ja) 2018-06-20 2023-10-30 ウーツェーベー ファルマ ゲーエムベーハー 置換されたアルコキシピリジニルインドールスルホンアミド

Also Published As

Publication number Publication date
IL295047A (en) 2022-09-01
JP2020504753A (ja) 2020-02-13
CA3045244A1 (en) 2018-07-05
CN116036078B (zh) 2025-09-02
US20230348384A1 (en) 2023-11-02
AU2017387695B2 (en) 2022-06-23
US20220127227A1 (en) 2022-04-28
IL267438B2 (en) 2023-07-01
RU2019123031A (ru) 2021-02-01
UY37554A (es) 2018-07-31
KR102537100B1 (ko) 2023-05-25
BR112019012550A2 (pt) 2019-11-12
UA127890C2 (uk) 2024-02-07
TW201831448A (zh) 2018-09-01
RU2019123031A3 (https=) 2021-03-22
KR20190098243A (ko) 2019-08-21
IL295047B2 (en) 2024-09-01
IL267438A (en) 2019-08-29
AU2022235580B2 (en) 2024-03-28
IL267438B1 (en) 2023-03-01
TWI754702B (zh) 2022-02-11
CR20190287A (es) 2019-08-06
US20220048858A1 (en) 2022-02-17
CO2019007829A2 (es) 2019-07-31
CN116036078A (zh) 2023-05-02
JP7270011B2 (ja) 2023-05-09
CN116283712A (zh) 2023-06-23
NZ753651A (en) 2022-10-28
CL2019001660A1 (es) 2019-10-25
JP2022003051A (ja) 2022-01-11
US12071404B2 (en) 2024-08-27
MX2019006190A (es) 2019-11-18
ECSP19044183A (es) 2020-01-31
CN110121499A (zh) 2019-08-13
PE20191475A1 (es) 2019-10-16
RU2767904C2 (ru) 2022-03-22
US11820746B2 (en) 2023-11-21
US11345662B2 (en) 2022-05-31
ZA201903466B (en) 2020-11-25
EA201991553A1 (ru) 2020-01-09
AU2022235580A1 (en) 2022-10-13
AR110592A1 (es) 2019-04-10
CN116283712B (zh) 2025-08-19
TN2019000165A1 (en) 2020-10-05
IL295047B1 (en) 2024-05-01
MY199872A (en) 2023-11-27
US20190345104A1 (en) 2019-11-14
CN110121499B (zh) 2022-12-20
WO2018122232A1 (en) 2018-07-05
AU2017387695A1 (en) 2019-06-06
PH12019501095A1 (en) 2019-12-02
EP3562820A1 (en) 2019-11-06

Similar Documents

Publication Publication Date Title
JP7270011B2 (ja) （アザ）インドール－、ベンゾチオフェン－、及びベンゾフラン－３－スルホンアミド
US11414392B2 (en) [6,6] fused bicyclic HDAC8 inhibitors
HK40091531B (zh) (氮杂)吲哚-、苯并噻吩-和苯并呋喃-3-磺酰胺类
HK40091531A (zh) (氮杂)吲哚-、苯并噻吩-和苯并呋喃-3-磺酰胺类
HK40010451B (en) (aza)indole-, benzothiophene-, and benzofuran-3-sulfonamides
HK40010451A (en) (aza)indole-, benzothiophene-, and benzofuran-3-sulfonamides
EA039985B1 (ru) (аза)индол-, бензотиофен- и бензофуран-3-сульфонамиды
BR112019012550B1 (pt) Compostos (aza)indol-, benzotiofeno- e benzofuran-3- sulfonamidas, uso de tais compostos e composição farmacêutica compreendendo tais compostos

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200218

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200218

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210114

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210210

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210423

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210817

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210915

R150 Certificate of patent or registration of utility model

Ref document number: 6946436

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250